PDCD1 and neoplasm: Because PD-1/PD-L1 inhibitors exhibited a higher tumor response, especially in patients with positive PD-L1 expression in tumors compared with negative PD-L1 expression, further phase III studies including Checkmate026, KEYNOTE-024, KEYNOTE-042, and IMpower110 were conducted to compare PD-1/PD-L1 inhibitors to platinum-doublet therapy in a front-line setting focused on patients with positive PD-L1 expression [29,30,31,32].